Key result
Use of ACE inhibitors or angiotensin-receptor blockers was not significantly associated with the overall risk of cancer (RR 0.96, 95% CI 0.90-1.03).
Why the study?
Does the use of ACE inhibitors or ARBs affect the overall risk of cancer?
Meta-Analysis (n=3,759,560)
Does the use of ACE inhibitors or ARBs affect the overall risk of cancer?
Relative Risk: 0.96 (95% CI 0.9–1.03)
This meta-analysis of observational studies found no significant association between ACE inhibitor or ARB use and overall cancer risk, supporting the general safety of these medications regarding oncogenesis.
No takes yet. Share an insight, caveat, or question.
Supports oncologic safety of ACE inhibitors/ARBs; leaves open need for randomized confirmation.
Yoon et al. (2011) conducted a meta-analysis in Cancer (n=3,759,560). ACE inhibitors or angiotensin-receptor blockers vs. No use of ACE inhibitors or angiotensin-receptor blockers was evaluated on Overall risk of cancer (RR 0.96, 95% CI 0.90-1.03). Use of ACE inhibitors or angiotensin-receptor blockers was not significantly associated with the overall risk of cancer (RR 0.96, 95% CI 0.90-1.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: